Ulinastatin protects against lps-induced acute lung injury by attenuating tlr4/nf-kb pathway activation and reducing inflammatory mediators

Shock

Volumn 50, Issue 5, 2018, Pages 595-605

  Cao, Chao ^a   Yin, Chengfen ^b   Shou, Songtao ^a   Wang, Jun ^a   Yu, Lechang ^a   Li, Xuening ^a   Chai, Yanfen ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Third Central Hospital   (China)

Author keywords

inflammatory response; Lipopolysaccharide; mechanism; NF kB signaling pathway; pulmonary damage; Toll like receptor 4

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MALONALDEHYDE; MESSENGER RNA; MYELOPEROXIDASE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; ULINASTATIN; VASCULAR CELL ADHESION MOLECULE 1; GLYCOPROTEIN; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEAS-2B CELL LINE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY; LIPOPOLYSACCHARIDE-INDUCED LUNG INFLAMMATION; LUNG EDEMA; LUNG PARENCHYMA; MACROPHAGE; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING; ACUTE LUNG INJURY; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; C57BL MOUSE; CYTOLOGY; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION;

ACUTE LUNG INJURY; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; GLYCOPROTEINS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 85053828548     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000001104     Document Type: Article

References (39)

1. Levy MM, Artigas A, Phillips GS, Rhodes A, Beale R, Osborn T, Vincent JL, Townsend S, Lemeshow S, Dellinger RP: Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: A prospective cohort study. Lancet Infect Dis 12(12):919-924, 2012.
2. Sadowitz B, Roy S, Gatto LA, Habashi N, Nieman G: Lung injury induced by sepsis: Lessons learned from large animal models and future directions for treatment. Expert Rev Anti Infect Ther 9(12):1169-1178, 2011.
3. Raghavendran K, Napolitano LM: Definition of ALI/ARDS. Crit Care Clin 27(3):429-437, 2011.
4. Needham DM, Colantuoni E, Mendez-Tellez PA, Dinglas VD, Sevransky JE, Dennison Himmelfarb CR, Desai SV, Shanholtz C, Brower RG, Pronovost PJ: Lung protective mechanical ventilation and two year survival in patients with acute lung injury: Prospective cohort study. BMJ 344:e2124, 2012.
5. Xie K, Yu Y, Huang Y, Zheng L, Li J, Chen H, Han H, Hou L, Gong G, Wang G: Molecular hydrogen ameliorates lipopolysaccharide-induced acute lung injury in mice through reducing inflammation and apoptosis. Shock 37(5):548-555, 2012.
6. Yang Q, Liu X, Liu M, Zhang L, Guan Y: Ulinastatin-mediated protection against zymosan-induced multiple organ dysfunction in rats. Biologicals 38(5):552-556, 2010.
7. Yang B, Gao M, Wang K, Jiang Y, Peng Y, Zhang H, Yang M, Xiao X: Intraintestinal administration of ulinastatin protects against sepsis by relieving intestinal damage. J Surg Res 211:70-78, 2017.
8. Linder A, Russell JA: An exciting candidate therapy for sepsis: Ulinastatin, a urinary protease inhibitor. Intensive Care Med 40(8):1164-1167, 2014.
9. Park JY, Jeon TJ, Hwang MW, Sinn DH, Oh TH, Shin WC, Choi WC: Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: A prospective, randomized trial. Pancreatology 14(4):263-267, 2014.
10. Wang N, Liu X, Zheng X, Cao H, Wei G, Zhu Y, Fan S, Zhou H, Zheng J: Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol 17(3):799-807, 2013.
11. Huang N, Wang F, Wang Y, Hou J, Li J, Deng X: Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res 182(2):296-302, 2013.
12. Gao C, Li R, Wang S: Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator. J Trauma Acute Care Surg 72(1):169-176, 2012.
13. LiW, Qiu X, Jiang H, Zhi Y, Fu J, Liu J: Ulinastatin inhibits the inflammation of LPS-induced acute lung injury in mice via regulation of AMPK/NF-kB pathway. Int Immunopharmacol 29(2):560-567, 2015.
14. Inoue K, Takano H: Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 19(4):513-520, 2010.
15. Yu Z, Rayile A, Zhang X, Li Y, Zhao Q: Ulinastatin protects against lipopolysaccharide -induced cardiac microvascular endothelial cell dysfunction via downregulation of lncRNA MALAT1 and EZH2 in sepsis. Int J Mol Med 39(5):1269-1276, 2017.
16. GuoW, Li Z, Xie X, Qin T, Wu Y, Li Z, Chai J, Yi F, Tan T, Zhu H, et al.: Urinary trypsin inhibitor attenuates acute lung injury by improving endothelial progenitor cells functions. Cell Physiol Biochem 36(3):1059-1068, 2015.
17. Huang C, Pan L, Lin F, Dai H, Fu R: Monoclonal antibody against Toll-like receptor 4 attenuates ventilator-induced lung injury in rats by inhibiting MyD88-and NF-kB-dependent signaling. Int J Mol Med 39(3):693-700, 2017.
18. Luo GJ, Yao WF, He Y, Luo CF, Li XY, Hei ZQ: Ulinastatin prevents acute lung injury led by liver transplantation. J Surg Res 193(2):841-848, 2015.
19. Kojima M, Gimenes-Junior JA, Chan TW, Eliceiri BP, Baird A, Costantini TW, Coimbra R: Exosomes in postshock mesenteric lymph are key mediators of acute lung injury triggering the macrophage activation via Toll-like receptor 4. FASEB J 32(1):97-110, 2018.
20. Ben DF, Yu XY, Ji GY, Zheng DY, Lv KY, Ma B, Xia ZF: TLR4 mediates lung injury and inflammation in intestinal ischemia-reperfusion. J Surg Res 174(2):326-333, 2012.
21. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT: Tolllike receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27(1):135-144, 2007.
22. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM: Golenbock DT.LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198(7):1043-1055, 2003.
23. Xie F, Min S, Chen J, Yang J, Wang X: Ulinastatin inhibited sepsisinduced spinal inflammation to alleviate peripheral neuromuscular dysfunction in an experimental rat model of neuromyopathy. J Neurochem 143(2):225-235, 2017.
24. Cao YZ, Tu YY, Chen X, Wang BL, Zhong YX, Liu MH: Protective effect of Ulinastatin against murine models of sepsis: Inhibition of TNF-a and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol 64(6):543-547, 2012.
25. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 179(3): 1855-1863, 2007.
26. Kim IK, Rhee CK, Yeo CD, Kang HH, Lee DG, Lee SH, Kim JW: Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharideinduced acute lung injury during neutropenia recovery. Crit Care 17(3):R114, 2013.
27. Wang SY, Li ZJ, Wang X, Li WF, Lin ZF: Effect of ulinastatin on HMGB1 expression in rats with acute lung injury induced by sepsis. Genet Mol Res 14(2):4344-4353, 2015.
28. Sun Y, Du YJ, Zhao H, Zhang GX, Sun N, Li XJ: Protective effects of ulinastatin and methylprednisolone against radiation-induced lung injury in mice. J Radiat Res 57(5):505-511, 2016.
29. Sun R, Li Y, Chen W, Zhang F, Li T: Total ginsenosides synergize with ulinastatin against septic acute lung injury and acute respiratory distress syndrome. Int J Clin Exp Pathol 8(6):7385-7390, 2015.
30. Qin ZS, Tian P, Wu X, Yu HM, Guo N: Effects of ulinastatin administered at different time points on the pathological morphologies of the lung tissues of rats with hyperthermia. Exp Ther Med 7(6):1625-1630, 2014.
31. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, et al.: Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133(2):235-249, 2008.
32. Cao C, Chai Y, Shou S, Wang J, Huang Y, Ma T: Toll-like receptor 4 deficiency increases resistance in sepsis-induced immune dysfunction. Int Immunopharmacol 54:169-176, 2017.
33. Zhu Q, He G, Wang J, Wang Y, Chen W, Guo T: Down-regulation of toll-like receptor 4 alleviates intestinal ischemia reperfusion injury and acute lung injury in mice. Oncotarget 8(8):13678-13689, 2017.
34. Luo Y, Che W, Zhao M: Ulinastatin post-treatment attenuates lipopolysaccharide-induced acute lung injury in rats and human alveolar epithelial cells. Int J Mol Med 39(2):297-306, 2017.
35. Badshah H, Ali T, Kim MO: Osmotin attenuates LPS-induced neuroinflammation and memory impairments via the TLR4/NFkB signaling pathway. Sci Rep 6:24493, 2016.
36. Wan J, Shan Y, Fan Y, Fan C, Chen S, Sun J, Zhu L, Qin L, Yu M, Lin Z: NF-kB inhibition attenuates LPS-induced TLR4 activation in monocyte cells. Mol Med Rep 14(5):4505-4510, 2016.
37. Cao W, Li M, Li J, Li C, Xu X, Gu W: Geranylgeranylacetone ameliorates lung ischemia/reperfusion injury by HSP70 and thioredoxin redox system: NF-kB pathway involved. Pulm Pharmacol Ther 32:109-115, 2015.
38. Rui M, Duan YY, Zhang XH, Wang HL, Wang DP: Urinary trypsin inhibitor attenuates seawater-induced acute lung injury by influencing the activities of nuclear factor-kBand its related inflammatorymediators. Respiration 83(4):335-343, 2012.
39. Yang Q, Liu X, Yao Z, Mao S, Wei Q, Chang Y: Penehyclidine hydrochloride inhibits the release of high-mobility group box 1 in lipopolysaccharide-activated RAW264.7 cells and cecal ligation and puncture-induced septic mice. J Surg Res 186(1):310-317, 2014.